KESTREL与KITE:布西珠单抗治疗糖尿病性黄斑水肿的两项III期关键试验52周结果
两项双盲、100周、多中心、阳性对照随机试验比较布西珠单抗与阿柏西普治疗糖尿病性黄斑水肿。52周时布西珠单抗6mg在最佳矫正视力变化上非劣于阿柏西普,更多患者维持12周给药,中心子区厚度改善更优,眼严重不良事件发生率低。
要点
- 布西珠单抗6mg在52周最佳矫正视力变化上非劣于阿柏西普(非劣效界值4个字母)。
- 超过半数布西珠单抗6mg患者负荷期后维持每12周给药。
- KITE中布西珠单抗6mg第40至52周中心子区厚度改善优于阿柏西普(P=0.001)。
核心结论
- 布西珠单抗6mg在糖尿病性黄斑水肿患者中显示稳健的视力增益和解剖学改善,总体获益/风险特征良好。
研究设计与样本
- 两项双盲、100周、多中心、阳性对照、随机试验:KESTREL(n=566)按1:1:1随机分配至布西珠单抗3mg、6mg或阿柏西普2mg;KITE(n=360)按1:1随机分配至布西珠单抗6mg或阿柏西普2mg。
- 布西珠单抗组接受5次负荷剂量每6周一次,随后每12周给药,若在预设评估访视发现疾病活动可调整至每8周;阿柏西普组接受5次每4周一次负荷剂量后固定每8周给药。
主要发现
- 第52周时,布西珠单抗6mg较基线的平均最佳矫正视力变化非劣于阿柏西普(非劣效界值4个字母):KESTREL中+9.2个字母 vs +10.5个字母;KITE中+10.6个字母 vs +9.4个字母(P<0.001)。
- 布西珠单抗6mg组更多患者达到中心子区厚度<280µm,持续存在视网膜下和/或视网膜内积液的患者较阿柏西普组更少。
- 负荷期后超过半数布西珠单抗6mg患者维持每12周给药。
- KITE中,布西珠单抗6mg在第40周至第52周中心子区厚度较基线变化上优于阿柏西普(P=0.001)。
- 眼严重不良事件发生率:KESTREL中布西珠单抗3mg为3.7%、布西珠单抗6mg为1.1%、阿柏西普为2.1%;KITE中布西珠单抗6mg为2.2%、阿柏西普为1.7%。
关键数值与推荐
- 主要终点为第52周最佳矫正视力较基线变化,非劣效界值4个字母。
- 次要终点包括维持每12周给药的患者比例、糖尿病视网膜病变严重程度量表评分变化以及解剖学和安全性结局。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare the efficacy and safety of brolucizumab with aflibercept in patients with diabetic macular edema (DME). DESIGN: Double-masked, 100-week, multicenter, active-controlled, randomized trials. METHODS: Subjects were randomized 1:1:1 to brolucizumab 3 mg/6 mg or aflibercept 2 mg in KESTREL (n = 566) or 1:1 to brolucizumab 6 mg or aflibercept 2 mg in KITE (n = 360). Brolucizumab groups received 5 loading doses every 6 weeks (q6w) followed by 12-week (q12w) dosing, with optional adjustment to every 8 weeks (q8w) if disease activity was identified at predefined assessment visits; aflibercept groups received 5 doses every 4 weeks (q4w) followed by fixed q8w dosing. The primary endpoint was best-corrected visual acuity (BCVA) change from baseline at Week 52; secondary endpoints included the proportion of subjects maintained on q12w dosing, change in Diabetic Retinopathy Severity Scale score, and anatomical and safety outcomes. RESULTS: At Week 52, brolucizumab 6 mg was noninferior (NI margin 4 letters) to aflibercept in mean change in BCVA from baseline (KESTREL: +9.2 letters vs +10.5 letters; KITE: +10.6 letters vs +9.4 letters; P < .001), more subjects achieved central subfield thickness (CSFT) <280 µm, and fewer had persisting subretinal and/or intraretinal fluid vs aflibercept, with more than half of brolucizumab 6 mg subjects maintained on q12w dosing after loading. In KITE, brolucizumab 6 mg showed superior improvements in change of CSFT from baseline over Week 40 to Week 52 vs aflibercept (P = .001). The incidence of ocular serious adverse events was 3.7% (brolucizumab 3 mg), 1.1% (brolucizumab 6 mg), and 2.1% (aflibercept) in KESTREL; and 2.2% (brolucizumab 6 mg) and 1.7% (aflibercept) in KITE. CONCLUSION: Brolucizumab 6 mg showed robust visual gains and anatomical improvements with an overall favorable benefit/risk profile in patients with DME.
引用
- Brown DM, Emanuelli A, Bandello F, et al. KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema. Am J Ophthalmol. 2022. PMID: 35038415. doi:10.1016/j.ajo.2022.01.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。